Global X Genomics & Biotechnology ETF(GNOM · ETF)
ETF quote, holdings, sector allocation, technicals, and options analytics.
Market data may be delayed, incomplete, or inaccurate. Not a recommendation to buy, sell, or hold any security. Verify quotes with your broker before trading. See Terms §17.
Snapshot
$49.14
- 52-Week Range
- $32.08 – $51.42
- YTD
- +7.61%
- IV Rank (30D)
- 10.39
- Straddle Price
- $4.80
- P/C Vol Ratio
- 1.33
Info
Global X Genomics & Biotechnology ETF (GNOM) ETF
- Exchange
- XNAS
- Inception
- 2019-04-05
- Has Options
- Yes
ETF Profile
holdings as of 2026-06-12
Holdings
52
AUM
$59.6M
Provider
Global X
Inception
2019-04-05
Exchange
XNAS
Data As Of
2026-06-12
Expense Ratio
—
Dividend Yield
1.22%
Distribution
Semi-Annual
Recent distributions
| Ex-Date | Pay Date | Amount | Type |
|---|---|---|---|
| 2025-12-30 | 2026-01-07 | $0.5912 | CD |
| 2025-06-27 | 2025-07-07 | $0.0083 | CD |
| 2021-12-30 | 2022-01-07 | $0.0065 | CD |
Asset Allocation
Top Holdings
top 50 of 52 holdings
| Symbol | Name | Weight % | Asset Class | Country |
|---|---|---|---|---|
| GH | GUARDANT HEALTH INC | 5.75% | Equity (US) | — |
| LEGN | LEGEND BIOTECH CORP-ADR | 5.41% | Equity (US) | — |
| ILMN | ILLUMINA INC | 4.83% | Equity (US) | — |
| TWST | TWIST BIOSCIENCE CORP | 4.58% | Equity (US) | — |
| BMRN | BIOMARIN PHARMACEUTICAL INC | 4.04% | Equity (US) | — |
| NTRA | NATERA INC | 3.99% | Equity (US) | — |
| VRTX | VERTEX PHARMACEUTICALS INC | 3.98% | Equity (US) | — |
| ARWR | ARROWHEAD PHARMACEUTICALS IN | 3.94% | Equity (US) | — |
| VCYT | VERACYTE INC | 3.77% | Equity (US) | — |
| QGEN | QIAGEN N.V. | 3.63% | Equity (US) | — |
| TECH | BIO-TECHNE CORP | 3.61% | Equity (US) | — |
| MRNA | MODERNA INC | 3.51% | Equity (US) | — |
| CRSP | CRISPR THERAPEUTICS AG | 3.45% | Equity (US) | — |
| TXG | 10X GENOMICS INC-CLASS A | 3.33% | Equity (US) | — |
| BNTX | BIONTECH SE-ADR | 3.26% | Equity (US) | — |
| PRAX | PRAXIS PRECISION MEDICINES I | 3.09% | Equity (US) | — |
| BEAM | BEAM THERAPEUTICS INC | 2.76% | Equity (US) | — |
| LLY | ELI LILLY & CO | 2.40% | Equity (US) | — |
| RARE | ULTRAGENYX PHARMACEUTICAL IN | 2.32% | Equity (US) | — |
| CAI | CARIS LIFE SCIENCES INC | 2.21% | Equity (US) | — |
| BLLN | BILLIONTOONE INC CL A | 2.04% | Equity (US) | — |
| — | GENSCRIPT BIOTECH CORP | 1.93% | Equity (US) | — |
| GILD | GILEAD SCIENCES INC | 1.84% | Equity (US) | — |
| — | ASTRAZENECA PLC | 1.80% | Cash/Money Market | — |
| WGS | GENEDX HOLDINGS CORP | 1.58% | Equity (US) | — |
| QURE | UNIQURE NV | 1.56% | Equity (US) | — |
| SRPT | SAREPTA THERAPEUTICS INC | 1.56% | Equity (US) | — |
| STOK | STOKE THERAPEUTICS INC | 1.42% | Equity (US) | — |
| NTLA | INTELLIA THERAPEUTICS INC | 1.39% | Equity (US) | — |
| BMY | BRISTOL-MYERS SQUIBB CO | 1.17% | Equity (US) | — |
| DHR | DANAHER CORP | 1.17% | Equity (US) | — |
| CDNA | CAREDX INC | 1.07% | Equity (US) | — |
| VIR | VIR BIOTECHNOLOGY INC | 1.01% | Equity (US) | — |
| WVE | WAVE LIFE SCIENCES LTD | 0.93% | Equity (US) | — |
| PSNL | PERSONALIS INC | 0.67% | Equity (US) | — |
| MRVI | MARAVAI LIFESCIENCES HLDGS-A | 0.53% | Equity (US) | — |
| BRKR | BRUKER CORP | 0.40% | Equity (US) | — |
| MYGN | MYRIAD GENETICS INC | 0.39% | Equity (US) | — |
| FLGT | FULGENT GENETICS INC | 0.38% | Equity (US) | — |
| BNTC | BENITEC BIOPHARMA INC | 0.37% | Equity (US) | — |
| A | AGILENT TECHNOLOGIES INC | 0.37% | Equity (US) | — |
| PACB | PACIFIC BIOSCIENCES OF CALIF | 0.36% | Equity (US) | — |
| RGNX | REGENXBIO INC | 0.31% | Equity (US) | — |
| MLAB | MESA LABORATORIES INC | 0.31% | Equity (US) | — |
| DGX | QUEST DIAGNOSTICS INC | 0.29% | Equity (US) | — |
| RCKT | ROCKET PHARMACEUTICALS INC | 0.29% | Equity (US) | — |
| LAB | STANDARD BIOTOOLS INC | 0.28% | Equity (US) | — |
| PRME | PRIME MEDICINE INC | 0.27% | Equity (US) | — |
| EDIT | EDITAS MEDICINE INC | 0.25% | Equity (US) | — |
| CRBU | CARIBOU BIOSCIENCES INC | 0.20% | Equity (US) | — |
Geographic Breakdown
Fund Holdings
Global X Genomics & Biotechnology ETF ·
NPORT-P period 2026-11-30
(filed 2026-04-29)
Net assets:
$52M
· 51 total positions
· equity 99.97%
· non-equity 2.39%
| # | Symbol | Issuer | Weight | Value |
|---|---|---|---|---|
| 1 | MODERNA INC COMMON STOCK | MODERNA, INC. | 7.86% | $4.1M |
| 2 | PRAXIS PRECISION MEDICINES I COMMON STOCK | Praxis Precision Medicines Inc | 6.23% | $3.3M |
| 3 | ARROWHEAD PHARMACEUTICALS IN COMMON STOCK | ARROWHEAD PHARMACEUTICALS, INC. | 5.69% | $3.0M |
| 4 | ILLUMINA INC COMMON STOCK | ILLUMINA, INC. | 5.13% | $2.7M |
| 5 | GUARDANT HEALTH INC COMMON STOCK | GUARDANT HEALTH, INC. | 4.71% | $2.5M |
| 6 | VERTEX PHARMACEUTICALS INC COMMON STOCK | VERTEX PHARMACEUTICALS INCORPORATED | 4.32% | $2.3M |
| 7 | BIOMARIN PHARMACEUTICAL INC COMMON STOCK | BIOMARIN PHARMACEUTICAL INC. | 4.31% | $2.3M |
| 8 | NATERA INC COMMON STOCK | NATERA, INC. | 3.91% | $2.0M |
| 9 | BIONTECH SE-ADR DEPOSITARY RECEIPT | BioNTech SE | 3.87% | $2.0M |
| 10 | AVIDITY BIOSCIENCES INC COMMON STOCK | Avidity Biosciences Inc | 3.75% | $2.0M |
| 11 | QIAGEN N.V. COMMON STOCK | Qiagen N.V. | 3.63% | $1.9M |
| 12 | CRISPR THERAPEUTICS AG COMMON STOCK | CRISPR Therapeutics AG | 3.48% | $1.8M |
| 13 | BIO-TECHNE CORP COMMON STOCK | BIO-TECHNE CORPORATION | 3.45% | $1.8M |
| 14 | BRISTOL-MYERS SQUIBB CO COMMON STOCK | BRISTOL-MYERS SQUIBB COMPANY | 2.65% | $1.4M |
| 15 | ALNYLAM PHARMACEUTICALS INC COMMON STOCK | ALNYLAM PHARMACEUTICALS, INC. | 2.51% | $1.3M |
| 16 | VERACYTE INC COMMON STOCK | Veracyte Inc | 2.39% | $1.3M |
| 17 | ELI LILLY & CO COMMON STOCK | ELI LILLY AND COMPANY | 2.34% | $1.2M |
| 18 | TWIST BIOSCIENCE CORP COMMON STOCK | Twist Bioscience Corp | 2.30% | $1.2M |
| 19 | GILEAD SCIENCES INC COMMON STOCK | GILEAD SCIENCES, INC. | 2.28% | $1.2M |
| 20 | ASTRAZENECA PLC COMMON STOCK | ASTRAZENECA PLC | 2.28% | $1.2M |
| 21 | BEAM THERAPEUTICS INC COMMON STOCK | Beam Therapeutics Inc | 2.21% | $1.2M |
| 22 | 10X GENOMICS INC-CLASS A COMMON STOCK | 10X Genomics Inc | 2.16% | $1.1M |
| 23 | LEGEND BIOTECH CORP-ADR DEPOSITARY RECEIPT | Legend Biotech Corp | 2.14% | $1.1M |
| 24 | ULTRAGENYX PHARMACEUTICAL IN COMMON STOCK | Ultragenyx Pharmaceutical Inc | 1.78% | $930431 |
| 25 | GENEDX HOLDINGS CORP COMMON STOCK | GeneDx Holdings Corp | 1.72% | $898332 |
Showing top 25 of 50 equity holdings.
Non-equity holdings
— 1 positions,
2.39% of NAV
| Category | Weight | Value | Positions |
|---|---|---|---|
| Repurchase agreement | 2.39% | $1.3M | 1 |
Daily issuer data also available
(2026-06-13)
via ETF Constituents
Price History
Seasonality
| Month | Avg Return | Years of Data |
|---|---|---|
| Jan | -1.62% | 10 |
| Feb | +0.45% | 10 |
| Mar | -5.60% | 10 |
| Apr | +5.88% | 10 |
| May | -1.05% | 10 |
| Jun | +2.18% | 10 |
| Jul | +2.66% | 9 |
| Aug | -0.40% | 9 |
| Sep | -6.68% | 9 |
| Oct | -0.39% | 9 |
| Nov | +2.14% | 10 |
| Dec | -2.43% | 10 |
Technical Indicators
Quick-reference for reading the values below. Indicators combine to confirm a view — no single one is a trade signal on its own.
Trend Indicators
- SMA 20 / 50 / 200 — price above = uptrend, below = downtrend. SMA 50 crossing SMA 200 is the golden/death cross.
- EMA 12 / 26 — faster-reacting averages; 12 above 26 is short-term bullish.
- MACD — bullish when MACD > signal (green badge), bearish when below. Divergence from price often precedes reversals.
- ADX (14) — trend strength regardless of direction. <20 range, 20–25 weak trend, 25–50 trend, >50 strong trend.
- +DI / −DI — +DI > −DI favors bulls; the reverse favors bears. Read alongside ADX.
Momentum Oscillators
- RSI (14) — <30 oversold, >70 overbought. 40–60 is neutral; trending names can stay extreme.
- Stochastic %K / %D — <20 oversold, >80 overbought. %K crossing %D is an early momentum signal.
- Williams %R — inverted scale: <−80 oversold, >−20 overbought.
Oscillators work best in range-bound markets; in strong trends they give premature reversal signals.
Volume & Volatility
- Bollinger Bands — price at upper band = overbought, lower = oversold. Narrow bands (squeeze) often precede expansion.
- OBV — cumulative volume; rising OBV confirms uptrend, falling OBV confirms downtrend. Divergence from price is a warning.
- Vol SMA 20 / Vol ROC — today's volume vs. 20-day average. Positive ROC with price move = conviction.
- ATR / True Range — average daily $ move; sizing and stop-loss reference.
- HV 20 / 30 / 60 — realized (historical) volatility. Compare to IV on the options cards: IV > HV = rich premium.
Confluence matters: trend + momentum + volume agreeing carries far more weight than any single indicator. For how these feed the spread scanner score, see the algorithm docs →
Trend Indicators
SMA 20: $47.62
SMA 50: $46.52
SMA 200: $44.62
Current: $48.95
EMA 12: $48.45
EMA 26: $47.66
MACD: 0.7862 | Signal: 0.0022
BULLISH
ADX (14): 20.10
WEAK TREND
+DI: 33.22
−DI: 20.96
Momentum Oscillators
RSI (14): 55.87
NEUTRAL
Stoch %K: 49.19
Stoch %D: 52.46
Williams %R: -50.04
Volume & Volatility
BB Upper: $51.43
BB Lower: $43.81
NEUTRAL
OBV: -290,048
Vol SMA 20: 13,311
Vol ROC: -62.14%
ATR: $1.22
True Range: $0.79
HV 20: 35.9%
HV 30: 32.4%
HV 60: 32.7%
Data Summary
Data Points: 500
Last Updated: 2026-06-12T21:15:08.447000
Date Range: 2024-06-14T00:00:00 – 2026-06-12T00:00:00
AI Analysis
Choose Frenzy-Fast™ for quick analysis or Frenzy-Pro™ for comprehensive analysis.
Analysis includes technical indicators, news sentiment, risk assessment, and specific price levels to watch.
News
Options Activity
- IV Rank (30D)
- 10.39
- IV Rank (7D)
- 47.47
- Avg IV
- 46.9%
- Straddle (30D)
- $4.80
- Straddle (7D)
- $3.50
- P/C Volume
- 1.33
Spread Scanner GPU
Each spread is ranked by a composite score built in three stages. Full documentation →
Stage 1 — Base Score (GPU scanner)
score = P(profit) × (credit / spread_width)
P(profit) from short leg delta (1 − |delta|), penalised above 85%. Credit uses mid-price to handle illiquid chains fairly.
Stage 2 — Skew Adjustment (±25% cap)
RR25 and BF25 from the live options chain. Put skew boosts bull puts, penalises bear calls. High butterfly boosts iron condors. Calendars are skew-neutral.
Stage 3 — Technical Overlay (±50% cap, 5 groups)
Group 1 · Directional Bias (±0.25)
- RSI <40 bullish / >60 bearish
- MACD crossover + histogram trend
- Price vs SMA 50 & SMA 200
Group 2 · Momentum (±0.10)
- Stochastic %K <20 / >80
- Williams %R <−80 / >−20
Group 3 · Volatility (up to −0.25 / +0.15)
- Blended ATR + straddle expected-move penalty
- Bollinger Band signal (+ counter-trend penalty)
- BB width — vol contraction boost for ICs
Group 4 · IV Regime (±0.15)
- IV rank ≥ 75 → strong boost for credit spreads
- IV rank < 25 → penalty (selling cheap vol)
Group 5 · Liquidity (penalty up to −0.10)
- Min open interest across all legs
- OI < 100 → −0.10 · OI < 500 → −0.05
score = base_score × skew_multiplier × tech_multiplier
Both multipliers are shown per spread. Beta is informational only — ATR already captures realized vol. Full algorithm documentation →
Enter a ticker to scan for optimal spread opportunities.
Evaluates all bull put, bear call, iron condor, and calendar spread combinations using GPU-accelerated analysis.
Volatility Surface
Enter a ticker to render the implied volatility surface.
IV Rank (7 DTE)
IV Rank (30 DTE)
Straddle Price (30 DTE)
Beta Analysis
- Beta (1Y vs SPY)
- 1.29
- Correlation (SPY)
- 58.1%
- R²
- 0.34
- Ann. Volatility
- 27.3%
- SPY Volatility
- 12.3%
High volatility - stock moves more than market
Beta & Alpha Over Time
Constituent Performance
Click any bar to view the full quote for that stock.
Constituents
| Symbol | Price | 1 Day | 1 Week | 1 Month |
|---|